Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2018

Open Access 01-12-2018 | Original investigation

Burden of cardiovascular risk factors and disease among patients with type 1 diabetes: results of the Australian National Diabetes Audit (ANDA)

Authors: Anthony Pease, Arul Earnest, Sanjeeva Ranasinha, Natalie Nanayakkara, Danny Liew, Natalie Wischer, Sofianos Andrikopoulos, Sophia Zoungas

Published in: Cardiovascular Diabetology | Issue 1/2018

Login to get access

Abstract

Background

Cardiovascular risk stratification is complex in type 1 diabetes. We hypothesised that traditional and diabetes-specific cardiovascular risk factors were prevalent and strongly associated with cardiovascular disease (CVD) among adults with type 1 diabetes attending Australian diabetes centres.

Methods

De-identified, prospectively collected data from patients with type 1 diabetes aged ≥ 18 years in the 2015 Australian National Diabetes Audit were analysed. The burden of cardiovascular risk factors [age, sex, diabetes duration, glycated haemoglobin (HbA1c), blood pressure, lipid profile, body mass index, smoking status, retinopathy, renal function and albuminuria] and associations with CVD inclusive of stroke, myocardial infarction, coronary artery bypass graft surgery/angioplasty and peripheral vascular disease were assessed. Restricted cubic splines assessed for non-linearity of diabetes duration and likelihood ratio test assessed for interactions between age, diabetes duration, centre type and cardiovascular outcomes of interest. Discriminatory ability of multivariable models were assessed with area under the receiver operating characteristic (ROC) curves.

Results

Data from 1169 patients were analysed. Mean (± SD) age and median diabetes duration was 40.0 (± 16.7) and 16.0 (8.0–27.0) years respectively. Cardiovascular risk factors were prevalent including hypertension (21.9%), dyslipidaemia (89.4%), overweight/obesity (56.4%), ever smoking (38.5%), albuminuria (31.1%), estimated glomerular filtration rate < 60 mL/min/1.73 m2 (10.3%) and HbA1c > 7.0% (53 mmol/mol) (81.0%). Older age, longer diabetes duration, smoking and antihypertensive therapy use were positively associated with CVD, while high density lipoprotein-cholesterol and diastolic blood pressure were negatively associated (p < 0.05). Association with CVD and diabetes duration remained constant until 20 years when a linear increase was noted. Longer diabetes duration also had the highest population attributable risk of 6.5% (95% CI 1.4, 11.6). Further, the models for CVD demonstrated good discriminatory ability (area under the ROC curve 0.88; 95% CI 0.84, 0.92).

Conclusions

Cardiovascular risk factors were prevalent and strongly associated with CVD among adults with type 1 diabetes attending Australian diabetes centres. Given the approximate J-shaped association between type 1 diabetes duration and CVD, the impact of cardiovascular risk stratification and management before and after 20 years duration needs to be further assessed longitudinally. Diabetes specific cardiovascular risk stratification tools incorporating diabetes duration should be an important consideration in future guideline development.
Appendix
Available only for authorised users
Literature
3.
4.
go back to reference de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diab Care. 2014;37(10):2843–63.CrossRef de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diab Care. 2014;37(10):2843–63.CrossRef
6.
go back to reference Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(Suppl 2):S14–21.CrossRefPubMed Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(Suppl 2):S14–21.CrossRefPubMed
9.
go back to reference Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. The sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.CrossRefPubMedPubMedCentral Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. The sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.CrossRefPubMedPubMedCentral
11.
go back to reference Jaiswal M, Divers J, Urbina EM, Dabelea D, Bell RA, Pettitt DJ, et al. Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: the SEARCH for diabetes in youth cohort study. Pediatr Diab. 2018;19(4):680–9. https://doi.org/10.1111/pedi.12633.CrossRef Jaiswal M, Divers J, Urbina EM, Dabelea D, Bell RA, Pettitt DJ, et al. Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: the SEARCH for diabetes in youth cohort study. Pediatr Diab. 2018;19(4):680–9. https://​doi.​org/​10.​1111/​pedi.​12633.CrossRef
17.
go back to reference Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50.CrossRefPubMed Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50.CrossRefPubMed
23.
go back to reference Zgibor JC, Ruppert K, Orchard TJ, Soedamah-Muthu SS, Fuller J, Chaturvedi N, et al. Development of a coronary heart disease risk prediction model for type 1 diabetes: the Pittsburgh CHD in type 1 diabetes risk model. Diab Res Clin Pract. 2010;88(3):314–21.CrossRef Zgibor JC, Ruppert K, Orchard TJ, Soedamah-Muthu SS, Fuller J, Chaturvedi N, et al. Development of a coronary heart disease risk prediction model for type 1 diabetes: the Pittsburgh CHD in type 1 diabetes risk model. Diab Res Clin Pract. 2010;88(3):314–21.CrossRef
24.
go back to reference Hernández M, López C, Real J, Valls J, Ortega-Martinez de Victoria E, Vázquez F, et al. Preclinical carotid atherosclerosis in patients with latent autoimmune diabetes in adults (LADA), type 2 diabetes and classical type 1 diabetes. Cardiovasc Diabetol. 2017;16:94.CrossRefPubMedPubMedCentral Hernández M, López C, Real J, Valls J, Ortega-Martinez de Victoria E, Vázquez F, et al. Preclinical carotid atherosclerosis in patients with latent autoimmune diabetes in adults (LADA), type 2 diabetes and classical type 1 diabetes. Cardiovasc Diabetol. 2017;16:94.CrossRefPubMedPubMedCentral
25.
go back to reference Ferreira I, Hovind P, Schalkwijk CG, Parving HH, Stehouwer CDA, Rossing P. Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort. Diabetologia. 2018;61(1):231–41. https://doi.org/10.1007/s00125-017-4470-5.CrossRefPubMed Ferreira I, Hovind P, Schalkwijk CG, Parving HH, Stehouwer CDA, Rossing P. Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort. Diabetologia. 2018;61(1):231–41. https://​doi.​org/​10.​1007/​s00125-017-4470-5.CrossRefPubMed
26.
go back to reference Bradley TJ, Slorach C, Mahmud FH, Dunger DB, Deanfield J, Deda L, et al. Early changes in cardiovascular structure and function in adolescents with type 1 diabetes. Cardiovasc Diabetol. 2016;15:31.CrossRefPubMedPubMedCentral Bradley TJ, Slorach C, Mahmud FH, Dunger DB, Deanfield J, Deda L, et al. Early changes in cardiovascular structure and function in adolescents with type 1 diabetes. Cardiovasc Diabetol. 2016;15:31.CrossRefPubMedPubMedCentral
28.
go back to reference Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentral Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentral
29.
go back to reference Maple-Brown LJ, Hughes JT, Ritte R, Barzi F, Hoy WE, Lawton PD, et al. Progression of kidney disease in indigenous Australians: the eGFR follow-up study. Clin J Am Soc Nephrol. 2016;11(6):993–1004.CrossRefPubMedPubMedCentral Maple-Brown LJ, Hughes JT, Ritte R, Barzi F, Hoy WE, Lawton PD, et al. Progression of kidney disease in indigenous Australians: the eGFR follow-up study. Clin J Am Soc Nephrol. 2016;11(6):993–1004.CrossRefPubMedPubMedCentral
30.
go back to reference Maple-Brown LJ, Cunningham J, Hodge AM, Weeramanthri T, Dunbar T, Lawton PD, et al. High rates of albuminuria but not of low eGFR in urban indigenous Australians: the DRUID Study. BMC Public Health. 2011;11(1):346.CrossRefPubMedPubMedCentral Maple-Brown LJ, Cunningham J, Hodge AM, Weeramanthri T, Dunbar T, Lawton PD, et al. High rates of albuminuria but not of low eGFR in urban indigenous Australians: the DRUID Study. BMC Public Health. 2011;11(1):346.CrossRefPubMedPubMedCentral
32.
go back to reference Gordis L. Epidemiology. 2nd ed. Philadelphia: W.B. Saunders Company; 2000. Gordis L. Epidemiology. 2nd ed. Philadelphia: W.B. Saunders Company; 2000.
35.
go back to reference Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med. 2012;9(10):e1001321.CrossRefPubMedPubMedCentral Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med. 2012;9(10):e1001321.CrossRefPubMedPubMedCentral
38.
go back to reference Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000.CrossRefPubMed Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000.CrossRefPubMed
39.
go back to reference Emerging risk factors collaboration, De Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, et al. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307(23):2499–506. Emerging risk factors collaboration, De Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, et al. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307(23):2499–506.
40.
go back to reference Heier M, Borja MS, Brunborg C, Seljeflot I, Margeirsdottir HD, Hanssen KF, et al. Reduced HDL function in children and young adults with type 1 diabetes. Cardiovasc Diabetol. 2017;16:85.CrossRefPubMedPubMedCentral Heier M, Borja MS, Brunborg C, Seljeflot I, Margeirsdottir HD, Hanssen KF, et al. Reduced HDL function in children and young adults with type 1 diabetes. Cardiovasc Diabetol. 2017;16:85.CrossRefPubMedPubMedCentral
44.
go back to reference Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdottir S, et al. Glycemic control and cardiovascular disease in 7454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diab Care. 2010;33(7):1640–6.CrossRef Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdottir S, et al. Glycemic control and cardiovascular disease in 7454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diab Care. 2010;33(7):1640–6.CrossRef
46.
go back to reference Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, Hu G. HbA1c and coronary heart disease risk among diabetic patients. Diab Care. 2014;37(2):428–35.CrossRef Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, Hu G. HbA1c and coronary heart disease risk among diabetic patients. Diab Care. 2014;37(2):428–35.CrossRef
52.
go back to reference Purnell JQ, Braffett BH, Zinman B, Gubitosi-Klug RA, Sivitz W, Bantle JP, et al. Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diab Care. 2017;40(12):1756–62. http://care.diabetesjournals.org/content/40/12/1756.long. Accessed 15 May 2018. Purnell JQ, Braffett BH, Zinman B, Gubitosi-Klug RA, Sivitz W, Bantle JP, et al. Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diab Care. 2017;40(12):1756–62. http://​care.​diabetesjournals​.​org/​content/​40/​12/​1756.​long. Accessed 15 May 2018.
53.
go back to reference Conway B, Miller RG, Costacou T, Fried L, Kelsey S, Evans RW, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diab Med. 2010;27(4):398–404.CrossRef Conway B, Miller RG, Costacou T, Fried L, Kelsey S, Evans RW, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diab Med. 2010;27(4):398–404.CrossRef
55.
go back to reference Holt SK, Lopushnyan N, Hotaling J, Sarma AV, Dunn RL, Cleary PA, et al. Prevalence of low testosterone and predisposing risk factors in men with type 1 diabetes mellitus: findings from the DCCT/EDIC. J Clin Endocrinol Metab. 2014;99(9):E1655–60.CrossRefPubMedPubMedCentral Holt SK, Lopushnyan N, Hotaling J, Sarma AV, Dunn RL, Cleary PA, et al. Prevalence of low testosterone and predisposing risk factors in men with type 1 diabetes mellitus: findings from the DCCT/EDIC. J Clin Endocrinol Metab. 2014;99(9):E1655–60.CrossRefPubMedPubMedCentral
61.
go back to reference Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil–trandolapril study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805–16. https://jamanetwork.com/journals/jama/fullarticle/197761. Accessed 15 May 2018. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil–trandolapril study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805–16. https://​jamanetwork.​com/​journals/​jama/​fullarticle/​197761. Accessed 15 May 2018.
64.
go back to reference Mohammedi K, Potier L, Belhatem N, Matallah N, Hadjadj S, Roussel R, et al. Lower-extremity amputation as a marker for renal and cardiovascular events and mortality in patients with long standing type 1 diabetes. Cardiovasc Diabetol. 2016;15:5.CrossRefPubMedPubMedCentral Mohammedi K, Potier L, Belhatem N, Matallah N, Hadjadj S, Roussel R, et al. Lower-extremity amputation as a marker for renal and cardiovascular events and mortality in patients with long standing type 1 diabetes. Cardiovasc Diabetol. 2016;15:5.CrossRefPubMedPubMedCentral
72.
go back to reference Sandsmark DK, Messe SR, Zhang X, Roy J, Nessel L, Lee Hamm L, et al. Proteinuria, but not eGFR, predicts stroke risk in chronic kidney disease: chronic renal insufficiency cohort study. Stroke. 2015;46(8):2075–80.CrossRefPubMedPubMedCentral Sandsmark DK, Messe SR, Zhang X, Roy J, Nessel L, Lee Hamm L, et al. Proteinuria, but not eGFR, predicts stroke risk in chronic kidney disease: chronic renal insufficiency cohort study. Stroke. 2015;46(8):2075–80.CrossRefPubMedPubMedCentral
73.
go back to reference Bouchi R, Babazono T, Nyumura I, Toya K, Hayashi T, Ohta M, et al. Is a reduced estimated glomerular filtration rate a risk factor for stroke in patients with type 2 diabetes? Hypertens Res. 2009;32(5):381–6. https://www.nature.com/articles/hr200930. Accessed 15 May 2018. Bouchi R, Babazono T, Nyumura I, Toya K, Hayashi T, Ohta M, et al. Is a reduced estimated glomerular filtration rate a risk factor for stroke in patients with type 2 diabetes? Hypertens Res. 2009;32(5):381–6. https://​www.​nature.​com/​articles/​hr200930. Accessed 15 May 2018.
Metadata
Title
Burden of cardiovascular risk factors and disease among patients with type 1 diabetes: results of the Australian National Diabetes Audit (ANDA)
Authors
Anthony Pease
Arul Earnest
Sanjeeva Ranasinha
Natalie Nanayakkara
Danny Liew
Natalie Wischer
Sofianos Andrikopoulos
Sophia Zoungas
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2018
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-018-0726-8

Other articles of this Issue 1/2018

Cardiovascular Diabetology 1/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.